Top Page
bioAffinity Technologies, Inc.
(NASDAQ:BIAF)
bioAffinity Technologies, Inc. (BIAF) vs. SPDR S&P 500 ETF (SPY)
bioAffinity Technologies, Inc. Business Overview & Revenue Model
bioAffinity Technologies, Inc. Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 8.81M | 9.36M | 2.53M | 4.80K | 0.00 | 0.00 |
| Gross Profit | 3.03M | 3.38M | 791.62K | 4.34K | -4.82K | -22.24K |
| EBITDA | -9.03M | -8.33M | -7.63M | -5.61M | -2.20M | -6.86M |
| Net Income | -9.74M | -9.04M | -7.94M | -8.15M | -6.33M | -7.27M |
Balance Sheet | ||||||
| Total Assets | 5.55M | 6.51M | 8.22M | 12.18M | 1.45M | 145.60K |
| Cash, Cash Equivalents and Short-Term Investments | 444.71K | 1.11M | 2.82M | 11.41M | 1.36M | 83.11K |
| Total Debt | 1.33M | 1.50M | 1.58M | 251.75K | 11.36M | 10.01M |
| Total Liabilities | 4.11M | 3.91M | 3.37M | 1.14M | 17.24M | 15.22M |
| Stockholders Equity | 1.44M | 2.60M | 4.86M | 11.04M | -15.79M | -15.07M |
Cash Flow | ||||||
| Free Cash Flow | -6.65M | -7.34M | -6.06M | -4.29M | -2.05M | -2.21M |
| Operating Cash Flow | -6.56M | -7.26M | -6.04M | -4.07M | -2.05M | -2.21M |
| Investing Cash Flow | -88.48K | -79.08K | -2.21M | -219.99K | 0.00 | -2.89K |
| Financing Cash Flow | 4.64M | 5.63M | -344.98K | 14.34M | 3.33M | 1.72M |
bioAffinity Technologies, Inc. Technical Analysis
bioAffinity Technologies, Inc. Risk Analysis
bioAffinity Technologies, Inc. Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | $26.08M | ― | -14.76% | ― | 27.05% | 55.03% | |
51 Neutral | $7.92B | -0.43 | -41.67% | 2.21% | 22.29% | -1.85% | |
50 Neutral | $17.04M | ― | -118.26% | ― | -25.02% | 85.08% | |
48 Neutral | $20.76M | ― | 77.20% | ― | -4.02% | -6.31% | |
48 Neutral | $13.65M | ― | -186.64% | ― | -1.90% | 87.72% | |
44 Neutral | $6.81M | ― | -1802.45% | ― | 4.99% | 22.58% | |
44 Neutral | $7.69M | ― | -809.29% | ― | ― | ― |
bioAffinity Technologies, Inc. Corporate Events
bioAffinity Technologies, Inc., a Delaware corporation, has prepared presentation materials for use in various presentations about the company’s operations and performance. These materials are intended for events such as the H.C. Wainwright 27th Annual Global Investment Conference scheduled from September 8, 2025, to September 10, 2025. The presentation materials, furnished as Exhibit 99.1, are part of a Current Report on Form 8-K and are not considered filed under the Securities Exchange Act of 1934. This announcement highlights the company’s efforts to engage with investors and stakeholders through strategic presentations, potentially impacting its market visibility and investor relations.
On September 3, 2025, bioAffinity Technologies announced that U.S. Medicine Magazine featured their CyPath® Lung test in its pulmonary issue, recognizing its potential to enhance lung cancer detection and reduce costs for the Department of Veterans Affairs. The test has shown high sensitivity, specificity, and accuracy in detecting early-stage lung cancer, with significant potential savings for healthcare systems by reducing unnecessary follow-up procedures. This recognition underscores the test’s value in improving patient outcomes and its economic benefits, particularly for veterans at higher risk of developing lung cancer.
On September 2, 2025, bioAffinity Technologies, Inc. announced an agreement with warrant holders to amend the Floor Price of its May and August 2025 Warrants, increasing it from $0.10 to $0.15. This amendment, effective as of August 12, 2025, resulted in a reduction of shares issuable upon exercise of the May 2025 Warrants from 53,377,497 to 35,584,997, while the August 2025 Warrants remain subject to shareholder approval.
On August 12, 2025, bioAffinity Technologies appointed Roberto Rios and John J. Oppenheimer to its Board of Directors, enhancing the company’s financial and clinical expertise. The appointments are part of a strategic move to bolster the company’s growth and development in diagnostics for lung diseases, following Gary Rubin’s resignation from the board.
On August 13, 2025, bioAffinity Technologies, Inc. entered into a securities purchase agreement with institutional and accredited investors to issue and sell Series B Convertible Preferred Stock and warrants in a private placement, raising approximately $1.2 million in gross proceeds. The company also executed a warrant inducement transaction with an existing investor, which involved exercising existing warrants at a reduced price and issuing new warrants, resulting in additional proceeds of $253,000. The proceeds from these transactions are intended for working capital and general corporate purposes, potentially strengthening the company’s financial position and supporting its operational goals.
On August 13, 2025, bioAffinity Technologies announced a significant increase in sales of its CyPath® Lung test, with July’s test volume surging 72% over the prior monthly average. Despite this growth, the company faces potential delisting from the Nasdaq Capital Market due to non-compliance with listing requirements, but plans to appeal the decision to stay its securities’ suspension.
On July 29, 2025, bioAffinity Technologies announced a case study where their CyPath® Lung test successfully detected Stage 1A pulmonary mucinous adenocarcinoma in a high-risk patient whose previous tests indicated a low probability of cancer. This case highlights CyPath® Lung’s ability to provide diagnostic clarity in cases where traditional methods are inconclusive, potentially leading to earlier and more effective treatment options for patients.
At the 2025 Annual Meeting of Stockholders held on July 25, 2025, bioAffinity Technologies, Inc. announced the approval of several key proposals by its stockholders. These included the election of seven directors, the ratification of an independent accounting firm, and amendments to the company’s Certificate of Incorporation to effect a reverse stock split and increase share issuance. The meeting also saw approval for the issuance of shares upon exercise of warrants and adjustments to anti-dilution provisions, reflecting strategic moves to strengthen the company’s financial structure and operational capabilities.
On July 23, 2025, bioAffinity Technologies announced a case study where their CyPath® Lung test successfully identified a Stage 1A neuroendocrine tumor in a patient’s lung, which was missed by other diagnostic tools. This highlights the test’s importance as an adjunct to traditional imaging and diagnostic methods, offering clarity in cases where other tools are inconclusive, thus potentially improving patient outcomes through early detection and treatment.
On July 22, 2025, bioAffinity Technologies announced that it received a notification of allowance from the Canadian Patent Office for a patent application related to methods of predicting lung cancer using flow cytometry. This patent, titled ‘System and Method for Determining Lung Health,’ protects the use of specific antibodies and porphyrin TCPP to label cell populations in sputum and utilize flow cytometry to detect lung cancer cells. The patent strengthens the company’s international protection for its diagnostic platform, particularly its flagship test, CyPath® Lung. This development is significant as lung cancer is the leading cause of cancer deaths in Canada, and the patent is expected to expand bioAffinity’s market presence in the region, enhancing shareholder value and highlighting the company’s focus on early cancer detection.
On July 15, 2025, bioAffinity Technologies announced it received a notification of allowance from the China National Intellectual Property Administration for a patent related to predicting lung cancer likelihood using flow cytometry. This patent positions the company to expand its proprietary diagnostic platform in China, a significant market with a high prevalence of smokers and lung cancer cases. The patent protects the use of specific antibodies and porphyrin TCPP in labeling cell populations in sputum to detect lung cancer cells, enhancing the company’s global patent portfolio and supporting its strategy to build long-term shareholder value through innovation and early cancer detection.